Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
6.76
-0.28 (-3.98%)
Sep 12, 2025, 4:00 PM EDT - Market closed

Sagimet Biosciences Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Net Income
-59.38-45.57-27.88-30.5-24.44-11.37
Upgrade
Loss (Gain) From Sale of Assets
------0.02
Upgrade
Loss (Gain) From Sale of Investments
-1.34-1.25-0.04-0.21--
Upgrade
Stock-Based Compensation
6.155.294.991.881.90.78
Upgrade
Other Operating Activities
0.150.150.140.130.880.12
Upgrade
Change in Accounts Payable
2.12-0.910.122.920.56-0.36
Upgrade
Change in Other Net Operating Assets
-1.93-0.14-1.11.3-0.620.44
Upgrade
Operating Cash Flow
-54.23-42.44-23.77-24.49-21.71-10.42
Upgrade
Sale of Property, Plant & Equipment
-----0.02
Upgrade
Investment in Securities
0.6-61.6812.58-32.01--
Upgrade
Investing Cash Flow
0.6-61.6812.58-32.01-0.02
Upgrade
Issuance of Common Stock
0105.8689.690.010.19-
Upgrade
Other Financing Activities
--1.05-3.52-0.09-1.25-
Upgrade
Financing Cash Flow
0104.8286.17-0.079.7468.89
Upgrade
Net Cash Flow
-53.630.774.98-56.57-11.9758.49
Upgrade
Levered Free Cash Flow
-35.55-29.73-15.08-13.21-14.27-5.96
Upgrade
Unlevered Free Cash Flow
-35.55-29.73-15.08-13.21-14.27-5.96
Upgrade
Change in Working Capital
0.2-1.05-0.984.21-0.060.08
Upgrade
Updated Aug 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q